8-K: Checkpoint Therapeutics Secures $14 Million in At-the-Market Registered Direct Offering

Checkpoint Therapeutics has entered into a definitive agreement for a $14 million registered direct offering with a healthcare-dedicated institutional investor.

Summary

• Checkpoint Therapeutics has agreed to sell 1,275,000 shares of common stock and pre-funded warrants for 6,481,233 shares, along with common warrants for 7,756,233 shares, to a single healthcare-focused institutional investor.
• The offering is priced at $1.805 per share and $1.8049 per pre-funded warrant, with common warrants exercisable at $1.68 per share.
• The company expects to receive gross proceeds of approximately $14 million from the offering.
• H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering, receiving a 7% cash fee, a 1% management fee, and warrants to purchase 465,374 shares.
• The offering is expected to close around January 31, 2024, pending customary closing conditions.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. While the company is raising needed capital, it comes with dilution and costs. The use of proceeds for the BLA resubmission is a positive, but the overall sentiment is tempered by the potential risks.

Positives

• The company is securing a significant capital injection of approximately $14 million.
• The offering is being led by a healthcare-dedicated institutional investor, indicating confidence in the company's prospects.
• The use of proceeds is intended for working capital and general corporate purposes, including funding the planned resubmission of its Biologics License Application (BLA) for cosibelimab.

Negatives

• The offering involves the issuance of a substantial number of new shares, which could dilute existing shareholders.
• The company is incurring significant fees and expenses related to the offering, including a 7% cash fee and a 1% management fee to the placement agent.
• The common warrants have an exercise price of $1.68, which could lead to further dilution if exercised.

Risks

• The closing of the offering is subject to customary closing conditions, which may not be met.
• The company's stock price could be negatively impacted by the dilution from the new share issuance.
• The company's ability to successfully resubmit its BLA for cosibelimab is not guaranteed.
• The company is dependent on third-party suppliers and contract manufacturers.

Future Outlook

The company intends to use the net proceeds of this offering for working capital and general corporate purposes, including funding the planned resubmission of its Biologics License Application (BLA) for cosibelimab.

Industry Context

This capital raise is a common strategy for clinical-stage biotech companies to fund ongoing research and development activities, particularly as they approach regulatory milestones. The involvement of a healthcare-dedicated institutional investor suggests a level of confidence in the company's pipeline and potential.

Comparison to Industry Standards

• The use of a registered direct offering is a common method for biotech companies to raise capital quickly.
• The pricing of the offering at-the-market is typical for such transactions, reflecting the current market price of the stock.
• The inclusion of warrants is a common incentive for investors in these types of offerings.
• The fees paid to the placement agent are within the typical range for such transactions.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• The company's ability to fund its operations and resubmit its BLA for cosibelimab is improved.
• The company's long-term prospects may be enhanced if the BLA is approved.

Next Steps

• The company will close the offering on or about January 31, 2024.
• The company will use the proceeds for working capital and general corporate purposes, including funding the planned resubmission of its BLA for cosibelimab.
• The company will file a prospectus supplement with the SEC.
• The company will apply to list the new shares on the Nasdaq Capital Market.

Key Dates

Keywords

registered direct offering, common stock, pre-funded warrants, common warrants, capital raise, biologics license application, cosibelimab, H.C. Wainwright & Co., institutional investor, dilution